Multimodale Therapie des Hochrisiko- und lokal fortgeschrittenen Prostatakarzinoms

Treatment of the high-risk and locally advanced prostate cancer is a challenge in daily practice. At 20–40%, patients with such tumor stages currently make up the majority of patients at high-volume centers. Due to COVID-19, the proportion of patients with this tumor stage will probably continue to increase in the next few years. In addition to adequate staging, selection of the best individual therapy is crucial to avoid local complications and ensure optimal oncological survival. Treatment is often carried out with a multimodal approach. The use of extended hormone therapy in the neoadjuvant setting is currently under evaluation in large phase III trials and remains open.